Kane Biotech submits supplemental application, data on its KBI Antibacterial Hard Surface Disinfectant to the Therapeutic Products Directorate of Health Canada to expand label claims to include additional sites of use such as hospital, food processing

WINNIPEG, Manitoba , December 15, 2011 (press release) – Kane Biotech Inc., a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce it has submitted a supplemental application and data on KBI Antibacterial Hard Surface Disinfectant to the Therapeutic Products Directorate of Health Canada for an amendment to already issued Drug Identification Number (DIN). The requested amendment is to expand the label claims to include additional sites of use such as Hospital, Food Processing, Medical Instruments, Institutional/Industrial and Barn.

This submission follows the Therapeutic Products Directorate issuance of DIN: 02374463 for KBI Antibacterial Disinfectant for the Canadian domestic market, which was previously announced.

"The submitted data package for Health Canada review includes the required supporting data on the efficacy of KBI Antibacterial Disinfectant against bacterial pathogens found in health care, food processing and institutional/industrial facilities" stated Gord Froehlich, President and CEO of Kane Biotech. "KBI Antimicrobial Disinfectant has a unique mode of action by breaking down the polysaccharide matrix (biofilm) thus making the exposed bacteria more susceptible to the antimicrobial killing in a global disinfectant market estimated to reach $2.9 Billion a year by 2017"

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and commercialization of products to prevent and remove biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and are involved in approximately 80% of all human bacterial infections. The healing of chronic wounds alone costs the United States health care system $20 Billion per year.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.